Corcept Therapeutics reports developments in cortisol modulation therapies for severe endocrinologic, oncologic, metabolic and neurologic disorders. The company markets Korlym for endogenous Cushing’s syndrome and Lifyorli, a relacorilant regimen approved with nab-paclitaxel for certain adults with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer.
Recurring news includes financial results, revenue guidance, clinical data from programs such as ROSELLA, DAZALS and MOMENTUM, FDA-related updates, medical-conference presentations, publications, patent matters and distribution arrangements tied to Korlym, Lifyorli and the company’s selective cortisol modulator pipeline.
Corcept Therapeutics (NASDAQ: CORT) announced that the ADA/EASD consensus report recommends targeted hypercortisolism screening for adults with difficult-to-control type 2 diabetes. Published October 2, 2026, the report recommends considering screening when diabetes remains treatment-resistant despite multiple medications.
The report cites CATALYST, which found hypercortisolism, or excessive cortisol activity, in 24 percent of 1,057 patients screened. Among 136 participants randomized to treatment, the blood sugar measure HbA1c declined by 1.47 percent with mifepristone versus 0.15 percent with placebo over 24 weeks. The report says mifepristone may benefit hyperglycemia management but identifies a need to better understand cortisol-directed therapy.
Corcept Therapeutics (CORT) announced a planned leadership transition in its Endocrinology division effective October 1, 2026.
Sean Maduck, President of Endocrinology, will retire from his role and remain as a senior commercial advisor to support a smooth handover. Justin Gunn, currently Vice President of Sales and Commercial Learning for Oncology, will become President, Endocrinology, join the Executive Team and report to CEO Joseph K. Belanoff, M.D.
Corcept Therapeutics (CORT) received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use recommending EU marketing authorization of Lifyorli (relacorilant) plus nab-paclitaxel for platinum-resistant ovarian cancer.
The recommendation is based on Phase 2 and pivotal Phase 3 ROSELLA data showing improved progression-free and overall survival versus nab-paclitaxel alone, with a safety profile consistent with nab-paclitaxel monotherapy. The European Commission is expected to issue a final approval decision in the fourth quarter of 2026.
S&P Dow Jones Indices will rebalance the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 before the market opens on September 21, 2026, to keep each index aligned with its target market-cap range.
Dell Technologies, Palo Alto Networks, Arista Networks, and Sandisk will join the S&P 100, while NIKE, Honeywell Aerospace, Simon Property Group, and Colgate-Palmolive exit. Bloom Energy, Everpure, and Illumina will enter the S&P 500, replacing Molson Coors Beverage, The Trade Desk, and Builders FirstSource, which move to the S&P SmallCap 600. Multiple constituents, including HubSpot, AGNC Investment, Corcept Therapeutics, Brinker International, Herc Holdings, Delek US Holdings, AXT, Arcutis Biotherapeutics, AtriCure, Capri Holdings, Boston Beer, and others shift among the S&P MidCap 400 and S&P SmallCap 600.
Corcept Therapeutics (NASDAQ:CORT) reported Q2 2026 revenue of $256.1 million, up 32% year over year, driven by $208.6 million from Korlym and its authorized generic and $47.6 million from newly launched Lifyorli. Net income was $43.0 million (diluted EPS $0.36), versus $35.1 million ($0.29) a year earlier.
Six‑month 2026 revenue reached $421.1 million, while higher operating expenses, mainly from the Lifyorli launch and Cushing’s investments, led to a six‑month operating loss of $8.3 million and net income of $11.2 million. The company raised its 2026 revenue guidance to $1.1–$1.2 billion and ended June 30, 2026 with $544.6 million in cash and investments.
Corcept highlighted FDA approval and early uptake of Lifyorli in platinum‑resistant ovarian cancer, a resubmitted NDA for relacorilant in Cushing’s syndrome with a PDUFA date of December 17, 2026, and multiple oncology, MASH and ALS trials with key readouts expected by the end of 2027.
Corcept Therapeutics (NASDAQ: CORT) announced it will report its second quarter 2026 financial results and provide a corporate update on July 29, 2026. The company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time), with advance registration required and a listen-only webcast and replay available via the Investors / Events section of Corcept.com.
Corcept Therapeutics (NASDAQ:CORT) resubmitted its New Drug Application to the FDA for relacorilant as a treatment for patients with Cushing’s syndrome. The filing includes additional analyses requested by the FDA, and Corcept expects a six-month review.
The resubmission is supported by positive data from the pivotal GRACE trial, the double-blind, placebo-controlled Phase III GRADIENT trial, a long-term extension study and earlier-stage studies. Corcept believes these data show meaningful, durable improvements in Cushing’s signs and symptoms and may avoid certain serious adverse events seen with existing drugs.
Corcept Therapeutics (NASDAQ:CORT) presented new data at the ADA 86th Scientific Sessions from its CATALYST and MOMENTUM trials in difficult-to-control type 2 diabetes and resistant hypertension.
Korlym treatment in patients with hypercortisolism led to statistically significant HbA1c and weight-related reductions, including numerically greater benefits in those receiving GLP-1 or tirzepatide, and highlighted high hypercortisolism prevalence in these cardiometabolic populations.
Corcept Therapeutics (NASDAQ:CORT) presented new Phase 3 ROSELLA overall survival data for Lifyorli (relacorilant) plus nab-paclitaxel in platinum-resistant ovarian cancer at ASCO 2026.
The combination reduced risk of death by 35% (HR 0.65; p=0.0004), with median overall survival of 16.0 months versus 11.9 months for nab-paclitaxel alone.
Prespecified subgroups, including patients with a taxane-free interval ≤6 months (HR 0.60) and those whose most recent regimen included a taxane (HR 0.67), also showed survival benefit without biomarker selection.
Lifyorli plus nab-paclitaxel received FDA approval in March 2026 for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic regimens including bevacizumab.
The regimen is listed as a preferred option in NCCN Guidelines. In ROSELLA, safety was comparable to nab-paclitaxel alone; key warnings include neutropenia, severe infections, adrenal insufficiency, exacerbation of glucocorticoid-treated conditions and embryo-fetal toxicity. Common adverse reactions (>20%) included decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash and decreased appetite.
Corcept Therapeutics (NASDAQ:CORT) will resubmit its New Drug Application (NDA) to the FDA for relacorilant as a treatment for patients with Cushing’s syndrome.
Following a complete response letter and additional data analyses, Corcept expects a new PDUFA date approximately six months after resubmission.